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AbstrACt
Introduction Gestational diabetes mellitus (GDM) is a 
common metabolic disorder occurring in up to 10% of 
pregnancies in the western world. Most women with GDM 
are asymptomatic; therefore, it is important to screen, 
diagnose and manage the condition as it is associated with 
an increased risk of maternal and perinatal complications. 
Diagnosis of GDM is made in the late second trimester or 
early third trimester because accurate diagnosis or risk 
stratification in the first trimester is still lacking. An increase 
in serum proinsulin may be seen earlier in pregnancy and 
before a change in glycaemic control can be identified. This 
study will aim to establish if fasting proinsulin concentrations 
at 16–18 weeks gestation will help to identify or risk stratify 
high-risk pregnant women with GDM.
Methods and analysis This is a prospective, 
longitudinal cohort study. Two oral glucose tolerance 
tests will be carried out at 16–18 and 24–28 weeks 
gestation in 200 pregnant women with at least one risk 
factor for GDM (body mass index>30 kg/m2, previous 
macrosomic baby (>4.5 kg), previous gestational 
diabetes, first degree relative with type 2 diabetes 
mellitus) recruited from antenatal clinics. Blood samples 
will be taken fasting and at 30 min, 1 and 2 hours 
following the 75 g glucose load. In addition, a fasting 
blood sample will be taken 6-weeks post delivery. 
All samples will be analysed for glucose, insulin, C 
peptide and proinsulin. Recruitment began in November 
2017. Optimal cut-off points for proinsulin to diagnose 
gestational diabetes according to National Institute 
for Health and Care Excellence (2015) criteria will be 
established by the receiver operating characteristic 
plot and sensitivity and specificity will be calculated to 
assess the diagnostic accuracy of proinsulin at 16–18 
weeks gestation.
Ethics and dissemination This study received ethical 
approval from the Wales Research Ethics Committee 
(Panel 6) (Ref. 17/WA/0194). Data will be presented 
at international conferences and published in peer-
reviewed journals.
trial registration number ISRCTN16416602; Pre-results.
IntroduCtIon 
Gestational diabetes mellitus (GDM) is a 
common metabolic disorder occurring in up 
to 10% of pregnancies in the Western world.1 
GDM is defined as any degree of carbohydrate 
intolerance with onset or first recognition 
during pregnancy. Most women with GDM 
are asymptomatic; hence, it is important to 
screen, diagnose and manage the condition 
as it is associated with an increased risk of 
maternal and perinatal complications such as 
pre-eclampsia, macrosomia, shoulder dystocia 
and neonatal hypoglycaemia. Diagnosis of 
GDM is made in the late second trimester or 
early third trimester because accurate diag-
nosis or risk stratification in the first trimester 
is still lacking, and in the UK women with a 
high risk of GDM are currently offered an 
oral glucose tolerance test (OGTT) at 24–28 
weeks gestation.2 
The risk factors that predispose to the devel-
opment of GDM include body mass index 
(BMI) >30 kg/m2, previous macrosomic baby 
strengths and limitations of this study
 ► This is a prospective, longitudinal cohort study re-
cruiting at a single site.
 ► It is the first study to assess the use of proinsulin 
as a biomarker for the identification and risk strat-
ification of gestational diabetes mellitus in early 
pregnancy in women with at least one risk factor for 
gestational diabetes mellitus.
 ► Proinsulin will be measured using sensitive and 
highly specific immunoassays, eliminating the in-
fluence of other beta-cell products observed with 
previous proinsulin assays.
 ► The recruitment of 200 pregnant women is planned. 
The study has been designed to be sufficiently pow-
ered to compare the early screening approach with 
the detection of gestational diabetes mellitus at 
24–28 weeks of gestation.
 ► The use of proinsulin will be evaluated in a cohort of 
women at high risk of developing gestational diabe-
tes mellitus and the study will be underpowered as 
a screening tool for all pregnant women.
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(>4.5 kg), previous gestational diabetes, family history of 
type 2 diabetes mellitus (T2DM) (first degree relative 
with diabetes) and certain ethnic groups. Current diag-
nostic criteria are a fasting plasma glucose concentration 
of ≥5.6 mmol/L or a 2 hour value of ≥7.8 mmol/L.2 Glyco-
sylated haemoglobin (HbA1c) cannot be used to diagnose 
GDM as HbA1c is insufficiently sensitive to substitute for 
OGTT as a screening test.3
Women who develop GDM have a high risk of 
future-compromised glycaemic control. A review of 
published studies indicated a 7.43-fold increase risk of 
postpartum diabetes in women with GDM compared 
with women with healthy glycaemic control during 
pregnancy4 and the incidence of postpartum diabetes 
in North America and Europe has indicated a prev-
alence rate of between 30% and 50% up to 15 years’ 
follow-up.5–7
Normal pregnancy is accompanied by a progressive 
increase in insulin resistance that begins midway through 
pregnancy and progresses through the second and third 
trimesters with resultant increase in insulin secretion to 
compensate for the acquired resistance. The levels of 
insulin resistance are not too dissimilar to that seen in 
individuals with T2DM.8 GDM then develops when the 
insulin supply is no longer adequate to maintain normal 
blood glucose regulation.
Proinsulin is a precursor molecule for insulin and is 
synthesised by the pancreatic beta cells. Proinsulin is 
an 86 amino acid peptide, incorporating the A and B 
chains of insulin in addition to C peptide between amino 
acid residues 31 and 65. Under normal circumstances, 
virtually all proinsulin is cleaved at residues 32–33 and 
65–66 to produce C peptide and insulin, although a 
small amount of intact proinsulin may also be released 
into the circulation along with des 31–32 split proinsulin 
and 32–33 split proinsulin. In the presence of insulin 
resistance, pancreatic beta-cell function is affected with 
disproportionately more proinsulin (both intact and 
split) being secreted compared with insulin as seen in 
subjects with T2DM.9
Previous studies investigating serum proinsulin 
measurements in pregnancy have studied pregnant 
women irrespective of individual risk which may 
account for varied findings.10–12 However, studies 
comparing the proinsulin concentrations of healthy 
pregnant women and those who have gestational 
diabetes have found that proinsulin concentrations 
at fasting are significantly elevated in GDM compared 
with control subjects.13 14 These studies however did not 
assess the use of proinsulin as a biomarker for GDM; 
rather they compare women already diagnosed with 
GDM with proinsulin measured only at 24–28 weeks. 
Therefore it is possible that an increase in serum proin-
sulin may be seen earlier in pregnancy and before a 
change in glycaemic control can be identified. Specifi-
cally targeting pregnant women that are high risk may 
make serum proinsulin measurements more sensitive 
and specific to identify those that will develop GDM at 
an earlier stage in their pregnancy and subsequently 
suitable for earlier intervention.
AIMs And objECtIvEs
This study will aim to establish if fasting proinsulin 
concentrations at 16–18 weeks gestation will help to 
identify or risk stratify high-risk pregnant women with 
GDM diagnosed according to National Institute for 
Health and Care Excellence (2015) criteria.2 It will also 
seek to establish if 30 min and/or 1 and 2 hour post oral 
glucose load proinsulin measurements at 16–18 weeks 
gestation can discriminate women with gestational 
diabetes and predict which women will need insulin 
to control hyperglycaemia. The relationship of the 
various risk factors to plasma proinsulin levels will also 
be evaluated.
The primary objective of the study is to test the hypoth-
esis that fasting intact proinsulin measurements at 16–18 
weeks gestation will discriminate or risk stratify gestational 
diabetes (diagnosed from an OGTT at 24–28 weeks) from 
women with normal glucose tolerance.
The secondary objectives are:
 ► To test the hypothesis that 30 min, 1 and 2 hour post 
75 g oral glucose load, proinsulin measurements 
at 16–18 weeks gestation can predict those women 
subsequently diagnosed with gestational diabetes at 
24–28 weeks.
 ► To test the hypothesis that fasting, 30 min and/or 1 
and 2 hour post oral glucose load, proinsulin meas-
urements at 16–18 weeks gestation can predict those 
women with gestational diabetes that will need insulin 
during pregnancy.
 ► To study the relationship of various risk factors to 
plasma proinsulin concentrations and gestational 
diabetes in the second and third trimesters of 
pregnancy.
MEthods And AnAlysIs
study design
This is a prospective, longitudinal cohort study 
(table 1). Study recruitment started on 14 November 
2017 and the study is expected to last until December 
2019.
Two OGTTs will be carried out at 16–18 and 24–28 
weeks gestation in 200 pregnant women with at least one 
risk factor for GDM (BMI >30 kg/m2, previous macro-
somic baby (>4.5 kg), previous gestational diabetes, first 
degree relative with T2DM) recruited from antenatal 
clinics within Abertawe Bro Morgannwg University Health 
Board, Wales. Women of ethnic origin considered to be 
high risk will need to have another mentioned risk factor 
to be eligible for inclusion in the study. Blood samples will 
be taken fasting and at 30 min, 1 and 2 hours following 
the 75 g glucose load. In addition, a fasting blood sample 
will be taken at 6-weeks post delivery. All samples will be 
analysed for glucose, insulin, C peptide and proinsulin. 
Both intact proinsulin and total proinsulin (the sum of 
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intact proinsulin, 32–33 split proinsulin and des 31–32 
split proinsulin) will be assayed.
setting and site selection
Recruitment of pregnant women will be via a study 
poster placed at antenatal clinics within Abertawe Bro 
Morgannwg University Health Board, Wales. Study proce-
dures will be carried out at a single site (Joint Clinical 
Research Facility, Swansea University).
Informed consent
Informed consent for each subject will be obtained 
prior to initiating any trial procedures. Potential partic-
ipants eligible to take part in the study will receive 
an invitation letter from their hospital consultant or 
midwife, along with a participant information leaflet 
and be given an oral explanation about the study from 
a research professional (usually a research nurse). 
Written informed consent is given by the participant by 
signing and dating a consent form which will be coun-
tersigned and dated by either a study nurse or principal 
investigator to confirm that the participant has the 
opportunity to ask questions and fully understands the 
nature of the study. Thereafter, a copy of the consent 
form will be given to each of the participants. Research 
professionals can facilitate the consent process for the 
study if authorised to do so on the site delegation log 
following appropriate training including good clinical 
practice (GCP). The consent process makes clear that 
the participant can withdraw from the trial whenever 
they wish without giving a reason and without affecting 
their future care in any way. The reasons for withdrawal 
will be documented, if known, and site staff will be 
encouraged to trace participants lost to follow-up and 
document the reasons for their loss whenever possible.
Each participant will receive an identification number 
to ensure confidentiality and any samples will be identi-
fied by only using only the identification number. Data 
will be recorded in a case record form.
Patient population
Pregnant women at 16–18 weeks gestation with at least 
one of the following risk factors for GDM will be studied. 
Those recruited will meet the following inclusion/exclu-
sion criteria:
Inclusion criteria
 ► BMI >30 kg/m 2.
 ► Previous macrosomic baby (>4.5 kg).
 ► Previous GDM.
 ► Family history of T2DM (first degree relative with 
diabetes).
Exclusion criteria
 ► Subjects unable or unwilling to sign informed consent.
 ► Known previous diabetes mellitus or on treatment 
with metformin.
 ► Known chronic infection like hepatitis or HIV or 
chronic kidney, liver or heart disease.
 ► Previous bariatric surgery.
Table 1 
Timepoint Enrolment
Visit 1 Visit 2 Visit 3
16–18 weeks gestation 24–28 weeks gestation 6 weeks post partum
Enrolment
  Eligibility screen x
  Informed consent x
Intervention
  OGTT (0, 30, 60 120 min) x* x
  Fasting blood sample x
Assessments
  OGTT glucose x x
  OGTT proinsulin x x
  OGTT C peptide x x
  OGTT insulin x x
  Fasting blood for glucose, 
proinsulin, C peptide, insulin
x
  Birth weight of baby x†
  Apgar score at birth x†
  Medication x x x
*Participants exceeding the National Institute for Health and Care Excellence (2015) gestational diabetes mellitus diagnostic thresholds at this 
visit will be withdrawn from the study and immediately referred back to their antenatal team for follow-up.
†Obtained from medical notes.
OGTT, oral glucose tolerance test.
 o
n
 19 Septem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-022571 on 29 August 2018. Downloaded from 
4 Peter R, et al. BMJ Open 2018;8:e022571. doi:10.1136/bmjopen-2018-022571
Open access 
Women who will be diagnosed with gestational diabetes 
at the first visit (16–18 weeks) will be withdrawn from the 
study and referred back to routine antenatal care.
study visits
Participants will be seen on three different occasions.
The first two visits will be at 16–18 weeks and 24–28 
weeks gestation. Participants will be asked to attend 
having fasted for 10 hours. On arrival at the clinical unit, 
a fasting blood sample will be taken. Patients will then 
be given a drink containing 75 g glucose. At 30 min, 1 
and 2 hours following the drink further blood samples 
will be taken. The 30 min sample has been included to 
allow capture of the peak plasma insulin response and for 
robust estimation of insulin sensitivity.
The third visit will be 6-week post delivery where partic-
ipants will be asked again to attend having fasted for 
10 hours. On this occasion, a fasting blood sample only 
will be taken. Additional data including birth weight of 
the baby, Apgar score at birth and medications including 
insulin doses just prior to birth will be collected.
laboratory measurements
Laboratory measurements for glucose, insulin, C peptide 
and proinsulin (total and intact) will be carried out in 
the Good Clinical and Laboratory Practice Accredited 
Diabetes Research Unit Cymru Laboratory based at 
Swansea University.
Glucose samples will be taken into fluoride oxalate 
tubes and will be measured using a glucose oxidase assay 
(YSI 2300 Stat Plus, Fleet, Hampshire, UK). Insulin, 
C peptide, total and intact proinsulin samples will be 
taken into EDTA tubes and measured using specific 
immunoassays using chemiluminescent labels (Invitron, 
Monmouth, UK).
safety evaluations and data monitoring
The data monitoring committee (DMC) will monitor the 
overall conduct of the trial, safeguarding the interests of 
the trial participants and assessing the safety and efficacy 
of the intervention. Patients identified as glucose intol-
erant at 16 weeks will be considered to have had pre-ex-
isting glucose intolerance and will be referred back to 
their antenatal team and excluded from further partici-
pation in the study. All serious adverse events (AEs) that 
occur during the study will be recorded and reported in 
accordance with local requirements and will be reported 
to the DMC. All AEs will be recorded on a case report 
form and reviewed as part of central data monitoring.
statistical analysis plan
To address the primary objective and the first secondary 
objective, glucose measurements following an OGTT at 
24–28 weeks will be used as the reference standard to clas-
sify GDM status.
Optimal cut-off points for proinsulin will be established 
by the receiver operating characteristic plot which plotted 
the proportion of true positives against the proportion 
of false positives. 95% CIs for the area under curve, 
sensitivity and specificity will be calculated to assess the 
diagnostic accuracy of total and intact proinsulin at 16–18 
weeks gestation.
The same approach will be used to address the second 
secondary objective, but with the use of insulin during 
pregnancy as the reference standard.
Logistic regression will be used to analyse the relationship 
of proinsulin concentrations at 16–18 weeks gestation and 
other individual risk factors for the development of GDM.
All the analysis and data preparation will be done using 
statistical analyses which will be performed by a statisti-
cian using SPSS V.22 which is validated statistical software 
for clinical trial studies.
Values will be checked for normality, applying suitable 
transformations as necessary. All statistical hypothesis 
tests will be performed at a 5% significance level. All 
available data from withdrawn subjects will be included 
in the analysis up to the time of withdrawal where 
possible.
sample size
Sample size was estimated with Buderer’s formula15 which 
used prevalence, level of clinically acceptable precision 
and a hypothesised level of sensitivity and specificity as 
the parameters for estimating sample size.
There were no direct estimates of GDM prevalence 
in the high-risk population. Prevalence of GDM in the 
Western world was estimated to be ~10%1 and the rela-
tive risk of developing GDM in women with one of the 
risk factors (BMI >30 kg/m2) was 2.74.16 There are also 
reports of women with a family history of diabetes having 
a >6-fold risk of developing gestational diabetes.17 There-
fore, we have estimated the prevalence of GDM in our 
target population to be ~30%. We took the conserva-
tive approach of basing our sample size estimation on 
hypothesised sensitivity rather than specificity. Since the 
estimated prevalence was lower than 50%, this approach 
would give a higher estimate of the number to be included 
in the study.
As a meaningful screening test, a sensitivity of 90% for the 
circulating concentration of total and intact proinsulin at 
16–18 weeks gestation for GDM is expected as established by 
glucose measurements following an OGTT at 24–28 weeks. 
The minimal clinically acceptable precision for estimate of 
sensitivity is 6%. We also expect loss to follow-up to be less 
than 10%.
Adjusted for possible loss to follow-up, a sample size of 
200 will be required to estimate with precision of ±0.06 for 
an expected sensitivity of 0.9 with the proinsulin test, at the 
significance level of 0.05, if the prevalence of GDM is not 
lower than 30%.
Patient and public involvement
In preparation for this study, the Public Reference Group of 
the Diabetes Research Unit Cymru was consulted and their 
opinions sought on the concept of the study and the study 
design.
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EthICs And dIssEMInAtIon
research governance
The study conforms with the Research Governance Frame-
works for England and Wales, and the principles of GCP 
outlined by the International Conference on Harmonisation 
(http://www. ich. org/). The participating National Health 
Service (NHS) Health Board has given NHS permission and 
will be responsible for auditing the study.
Publication
In accordance with good practice, we have registered the 
GDM study in a public registry at International Standard 
Randomised Control Trial Number (ISRCTN 16416602). 
This is a diagnostic accuracy study and findings will be 
reported according to the Standards for Reporting of Diag-
nostic Accuracy Studies (STARD) guideline.18 We shall 
present study findings at national and international confer-
ences and publish as widely as possible in open access, 
peer-reviewed journals. Any published results will be made 
available to study participants from their study nurse on 
request (this is made clear in the patient information sheet) 
and any results will also be made available on the Diabetes 
Research Unit Cymru website (www. diabeteswales. org. uk) 
with a direct link to any publication and with a summary in 
lay language.
dIsCussIon
A recent systematic review and meta-analysis19 have shown 
that there is no good evidence for any of the diagnostic 
criteria for early onset GDM and have suggested the use of 
a fasting glucose of 6.1–6.9 mmol/L in the first trimester. 
Others20 have tried to develop a prediction model for 
obese women at high risk of GDM to facilitate targeted 
interventions.
Current practice is that pregnant women with at least 
one risk factor for GDM have an OGTT at 24–28 weeks 
and a fasting glucose measurement 6 weeks post delivery. 
It is not unusual for some patients having an OGTT at 28 
weeks to have glucose levels above 10 mmol/L indicating 
that they have been hyperglycaemic for some time and 
therefore it would be useful if we could reasonably iden-
tify at an earlier stage those women who will develop GDM 
and also those that would require insulin to control hyper-
glycaemia. This would help manage scarce resources, 
as those that are unlikely to require insulin could be 
followed up by experienced allied healthcare profes-
sionals like specialist midwives while those that require 
insulin could be followed up by diabetologists and/or 
diabetes specialist nurses earlier in their pregnancy. It 
will also be useful to revisit the pathophysiology of GDM 
with respect to the onset of insulin resistance and corre-
sponding insulin response at the various stages of preg-
nancy. Moreover, proinsulin assays have become more 
specific; thus, proinsulin can now be reliably measured by 
well-characterised immunoassays. This paper summarises 
the current approved protocol.
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